In addition, we observed that patients that received more than three lines of therapy and those with hypoalbuminemia at diagnosis of multiple myeloma had a worse outcome compared to patients with a normal value of albumin and those that received one or two lines of therapy. This evidence concerns the gene ALB and plasma cell myeloma.